Document is current
Any future updates will be listed below
-
Authors
Barger, Diana https://orcid.org/0000-0001-8491-3963
Hessamfar, Mojgan
Neau, Didier
Vareil, Marc-Olivier
Lazaro, Estibaliz
Duffau, Pierre
Rouanes, Nicolas
Leleux, Olivier
Le Marec, Fabien
Erramouspe, Marie
Wittkop, Linda
Dabis, François
Bonnet, Fabrice
-
Funding
Funding for this research was provided by:
Sidaction
Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- License Information
-
More Information
Article History
Received: 31 October 2019
Accepted: 11 June 2020
First Online: 10 July 2020
Ethics approval and consent to participate
: A local ethics committee approved the study’s protocol (Comité de Protection de Personnes Sud-Ouest et Outre-Mer III) on September 18th 2017. The French National Commission on Informatics and Liberty, an independent administrative regulatory body charged with ensuring that data privacy laws are applied to the collection, storage, and use of personal data, was requested in late 2017 and approval was granted on March 12th, 2018. All study participants provided written informed consent prior to inclusion in the ANRS CO3 Aquitaine cohort and tacit consent to participate in the QuAliV ancillary study.
: Not applicable.
: DB has received speaking fees from Gilead. FB declares to have received reimbursement for attending a symposium from ViiV Healthcare, Gilead, Bristol-Myers Squib, Merck and Janssen; speaking fees and consultancy fees from ViiV Healthcare, Gilead, Bristol-Myers Squib, Merck and Janssen; and funds for research from Gilead and ViiV Healthcare. The other authors declare that they have no competing interests.
